Thalia Tx on BioBizz Buzz

Our CEO David Solomon recently joined host Mike Ward on BioBiz Buzz to talk all things RNA gene silencing, cardiovascular risk, and the road ahead for Thalia Therapeutics.

The conversation covers why Lp(a) remains such a stubborn problem despite widespread statin use, how our once-yearly dual-target siRNA approach could change that, and what it takes to build a serious RNA therapeutics company from the ground up.

It's a wide-ranging episode — from the science and regulatory landscape through to pipeline strategy, big pharma partnerships, and our longer-term ambitions.